Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06712004 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Dose-Response Controlled Trial of Bevifibatide for Acute Ischemic Stroke

Study acronym: BCAIS-I
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated July 17, 2025 (before its estimated September 1, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Eligibility criteria shortened, about 11 wordsv3 See this version in full on ClinicalTrials.gov ↗
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Dec 15, 2024 to Feb 10, 2025 · Site details revisedv2 Show 2 more changesShow less
    • Start date changed from estimate of Dec 15, 2024 to Feb 10, 2025
    • Site details revised
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Zhujiang Hospital
72 trials monitored
See 5 trials at risk
Stroke
3,289 trials monitored
See 141 trials at risk
BCAIS-I is a single-center, randomized, double-blind, dose-response controlled clinical Trial, to preliminarily explore the efficacy of two different maintenance doses of bevifibatide citrate injection in improving 90-day neurological outcomes and the incidence of symptomatic intracranial hemorrhage in patients with acute ischemic stroke without large or medium-sized vessel occlusion, aiming to identify a dosing regimen that maintains therapeutic efficacy while minimizing the rates of symptomatic intracranial hemorrhage and serious adverse events, thereby providing dosing evidence for future large-scale randomized controlled trials.
Trial Details
NCT Number NCT06712004
Lead Sponsor Zhujiang Hospital
Conditions Ischemic Stroke, Acute, Ischemic Stroke, Cerebral Infarction, Brain Diseases
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov